- cafead   Sep 15, 2021 at 10:52: AM
via Swiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in the US, hoping to expand the number of women eligible for this type of therapy.
article source
article source